MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration's final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effect. MediPharm Labs has already supplied product for over 10 active clinical trials, including a U.S. National Institutes of Health funded study, and has completed multiple API and clinical trial material shipments to the United States.